Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
Dr. Igor Fisch to Present Data on Using the SURE CHO-Mplus Combinatorial Library to Address a Broad Range of Protein Production Bottlenecks
Geneva, Switzerland (PRWEB) October 24, 2013
Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s president and CEO, Igor Fish, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for Improved Recombinant Protein Production” on Tuesday, November 5 at 4:45 PM at the BIO-Europe 2013 Partnering Conference being held November 4 – 6, at the Messe Wien Exhibition and Congress Center in Vienna, Austria. The Company will be also taking part in the pre-scheduled partnering meetings.
Stable, high-level production of recombinant proteins requires not only elevated transcription, but also cellular systems that can accommodate all of the protein folding, metabolic, secretory transport and post-translational processing requirements of any given protein. These requirements can vary significantly from protein to protein. Leveraging data from the completed SURE CHO-M Genome and Transciptome, Selexis has engineered the SURE CHO-Mplus libraries to address expression issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration. With these libraries, Selexis has been able to significantly boost expression over broad range of proteins, including large multimeric structural proteins and and difficult to express proteins.
Companies or individuals attending BIO-Europe can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bioeurope/index.php
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:
- Visit http://www.selexis.com
- Follow us on Twitter @selexisSA
- Become a fan at http://www.facebook.com/SelexisSA
# # #
For the original version on PRWeb visit: http://www.prweb.com/releases/selexis_bio_europe/protiens_antibodies/prweb11264432.htm